spacer
home > ict > winter 2008 > patients are a virtue
PUBLICATIONS
International Clinical Trials

Patients Are a Virtue

Considering whether less haste in the short-term might actually improve speed-to-market, Mike Macnamee of LCG Bioscience urges the incorporation of patient studies into early stage clinical research

Although it is clear that there are many benefits of using patients in the early stages of clinical trials, it is also evident from recent discussions between sponsors and researchers that the use of patients before Phase II is still very limited. One of the reasons for this is that patient studies can be more time consuming to conduct, and this is an industry driven by speed. Additionally, while volunteer trials are well understood and the outcomes easily interpreted, patient trials are a new departure and generate a wealth of data that can create uncertainty in interpretation for both sponsor and regulatory authorities.

STOPPING EARLY STAGE TRIALS

One of the most effective ways in which pharmaceutical companies can hope to improve the efficiency of their development programmes is to terminate any project that is destined to fail as soon as possible. However, it is difficult in traditional drug development to distinguish winners from losers. And although it is late stage failures that cause the most angst for drug developers, there could be just as many promising compounds with useful indications that are dropped at the early stages because there is insufficient evidence of biological activity to justify the risk versus benefit ratio of their progression through the regulatory process.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Mike Macnamee is Chief Executive of LCG Bioscience, a provider of exploratory clinical research in volunteers and patient populations to the biotech and pharma industry. A graduate from Edinburgh in 1979 with a BSc in Psychology, he then gained an MSc in Pharmacology at London University, before returning to Edinburgh to complete his doctorate in Neuropharmacology (1984) at the Rosalin Institute. Mike founded LCG in 1993 and went on to create the Research Medicine Group for Serono. He has extensive experience in the development of both biological and chemical compounds targeting debilitating disease and has worked extensively across disciplines and cultures internationally. He led LCG to full independence through a successful MBO in 2005.
spacer
Dr Mike Macnamee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement